

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com



www.rockland.com tech@rockland.com +1 484.791.3823

Datasheet for XGAL-0100 X-Gal (Beta-Galactosidase Substrate)

Overview

Description:	X-Gal (Beta-Galactosidase Substrate) - XGAL-0100
Item No.:	XGAL-0100
Size:	100 mg
Applications:	Gene Editing, IHC

Product Details

Background:	X-Gal (5-Bromo-4-chloro-3-indolyl β -D-galactopyranoside) is a chromogenic substrate for the β -galactosidase enzyme, commonly used in molecular biology for blue-white screening of recombinant bacterial colonies and other reporter assays. When hydrolyzed by β -galactosidase, X-Gal produces an insoluble blue precipitate.
Synonyms:	5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside

Target Details

Purity/Specificity:	Purity: >99.0% (enzymatic), Melting Range: 232° to 234° C, Solubility: 2% in DMF, Molecular
	Weight: 408.64, Grade: Ultrapure

Application Details

Tested Applications:	Gene Editing
Suggested Applications:	IHC (Based on references)
ELISA:	1X
IHC:	1X
WB:	1X
Other:	Use by 30APR2023

Formulation



www.rockland.com tech@rockland.com +1 484.791.3823

Physical State:	Solid
Concentration:	Neat

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store container at -20° C prior to opening. Protect from moisture and light. No special shipping conditions or precautions are required.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Bottle X-Gal (Beta-Galactosidase Substrate)

Order online now!

www.rockland.com tech@rockland.com +1 484.791.3823



Immunohistochemistry

Neural ensembles in IL reactive to S+ or S- following the activity-targeted disruption by Daun02. Each of the four experimental groups, prepared and used for the Daun02 disruption and Post-disruption tests I, was further randomly divided into three groups defined by the type of final Fos induction condition (S+, S- or No S+/S-). The rats were exposed to S+, S- or No S+/S- (control), then deeply anesthetized and euthanized. Brains were collected, sectioned (40 µm), processed for Fos immunohistochemistry. Fos-positive nuclei from sampling areas around the IL microinjection sites were quantified double-blindly. X-gal (p/n XGAL-0100). The average numbers of Fos-positive nuclei per mm2 were calculated for each rat and used for statistical analyses. Yellow arrows represent typical Fos-positive nuclei. Group means of these average numbers (+SEM) are depicted. N = 7–9, each. *p<0.05–0.01 (vs. No active lever/light-cue). Figure 3. PMID: 27938664.



Order online now!

www.rockland.com tech@rockland.com +1 484.791.3823



Immunohistochemistry

Omission cue-induced suppression (OCIS) procedures for localization and phenotypic characterization of omission cue-reactive neurons in IL. All data are mean and SEM. Gray open circles on bar charts depict individual datapoints. a, b, c Timeline and schedule. d Target sites. e, f Representative sections. g Effects of cocaine S-, alcohol S-, and well-habituated odor on neural activation in IL as indicated by Fos immunohistochemistry. n = 10,9,8,9,6,6. Two-way between-subjects ANOVA: Training (F (2,42) = 4.81, P < 0.05) and Cue-Test (F(1,42) = 28.67, P < 0.001) main effects, and Training x Cue-Test interaction (F (2,42) = 3.77, P < 0.05). *P < 0.001 vs. No S-. Tuckey HSD test. h, i, j Neural phenotypes in IL reactive to cocaine or alcohol S- as indicated by in situ hybridization via 4-plex RNAscope[®] targeting c-fos, Slc17a7, Slc32a1, and CHAT, as markers for "S- reactive", "glutamatergic (GLU)", "GABAergic (GABA)", and "cholinergic (ACh)" nuclei. Each nucleus was identified by DAPI. For statistical analyses, total numbers of nuclei per mm2 that satisfied each phenotypic criterion were used. For graphic representations, percentages of each phenotype within a specific "parent" phenotype were used. h Percentages of different phenotypes within all DAPIpositive nuclei. n = 7,8,15. Individual data-points are not overlaid on the right panel for clarity because n = 15. For this panel, data from rats tested for cocaine S- and alcohol Swere pooled to represent the overall percentages of different phenotypes independent of neural activity. Twoway mixed ANOVA: Phenotype (F(4,52) = 532.79, P < 0.001), but not Group (F(1,13) = 4.05, NS) or Group x Phenotype interaction (F(4,52) = 0.34, NS). n = 7,8. i Percentages of Sreactive nuclei within different phenotypes. Two-way mixed ANOVA: Phenotype (F(3,39) = 38.62, P < 0.001), but not Group (F(1,13) = 2.5, NS) or Group x Phenotype interaction (F (3,39) = 1.74, NS). j Percentages of different neural phenotypes within S- reactive nuclei. Two-way mixed ANOVA: Phenotype (F(3,39) = 27.77, P < 0.001), but not Group (F(1,13) = 2.20, NS) or Group x Phenotype interaction (F(3,39) = 2.04, NS). n = 7,8. X-gal (5-bromo-4-chloro-3indolyl β -d-galactopyranoside) (p/n XGAL-0100). Fig 3. PMID: 31477694.

References



www.rockland.com tech@rockland.com +1 484.791.3823

- Laque A et al. Anti-relapse neurons in the infralimbic cortex of rats drive relapse-suppression by drug omission cues. *Nat Commun.* (2019)
- Suto, N et al. Distinct memory engrams in the infralimbic cortex of rats control opposing environmental actions on a learned behavior. *ELife* (2016)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.